Furthermore, how patients whose tumors have high TMB as well as MDM2 amplification would fare on checkpoint inhibitors is unclear; however, one of our previously reported patients with MDM2 amplification who demonstrated hyperprogression with anti–PD-L1 immunotherapy had a high TMB.22 Finally, an issue that merits prospective exploration is how a combination of MDM2 and checkpoint inhibitors would affect the risk of hyperprogression in patients whose cancers bear an MDM2 amplification. This evidence concerns the gene MDM2 and cancer.